Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
162.2 USD | +0.87% | -0.41% | +4.58% |
03:43pm | AbbVie, Gilgamesh Pharmaceuticals Partner to Develop Therapies for Psychiatric Disorders | MT |
May. 09 | Medincell: share price rises on resumption of trading | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.58% | 284B | |
+29.30% | 684B | |
+29.44% | 568B | |
-3.97% | 361B | |
+18.48% | 329B | |
+15.90% | 240B | |
+9.33% | 208B | |
-7.16% | 200B | |
+7.70% | 166B | |
-1.39% | 159B |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- AbbVie Says EMA's Committee Supports Approval of Upadacitinib for Treatment of Chronic Inflammatory Disease of the Spine